Business Description
Kintara Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US49720K2006
Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.61 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 80.2 | |||||
| 3-Year EPS without NRI Growth Rate | 81.2 | |||||
| 3-Year FCF Growth Rate | 80.3 | |||||
| 3-Year Book Growth Rate | 74 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 64.43 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.17 | |||||
| 9-Day RSI | 71.56 | |||||
| 14-Day RSI | 65.31 | |||||
| 6-1 Month Momentum % | 75.11 | |||||
| 12-1 Month Momentum % | -95.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.45 | |||||
| Quick Ratio | 2.45 | |||||
| Cash Ratio | 2.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -338.8 | |||||
| Shareholder Yield % | -88.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -506.08 | |||||
| ROA % | -198.2 | |||||
| ROIC % | -1218.78 | |||||
| 3-Year ROIIC % | -1219.42 | |||||
| ROC (Joel Greenblatt) % | -1218.78 | |||||
| ROCE % | -464.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.05 | |||||
| EV-to-EBITDA | -2.06 | |||||
| EV-to-Forward-Revenue | 0.85 | |||||
| EV-to-FCF | -2.42 | |||||
| Price-to-Net-Cash | 178.06 | |||||
| Earnings Yield (Greenblatt) % | -48.78 | |||||
| FCF Yield % | -59.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kintara Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.02 | ||
| Beta | 0 | ||
| Volatility % | 159.55 | ||
| 14-Day RSI | 65.31 | ||
| 14-Day ATR (€) | 0.437054 | ||
| 20-Day SMA (€) | 5.728449 | ||
| 12-1 Month Momentum % | -95.23 | ||
| 52-Week Range (€) | 2.449999 - 140.699999 | ||
| Shares Outstanding (Mil) | 55.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kintara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kintara Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kintara Therapeutics Inc Frequently Asked Questions
What is Kintara Therapeutics Inc(STU:3DMA)'s stock price today?
The current price of STU:3DMA is €7.12. The 52 week high of STU:3DMA is €140.70 and 52 week low is €2.45.
When is next earnings date of Kintara Therapeutics Inc(STU:3DMA)?
The next earnings date of Kintara Therapeutics Inc(STU:3DMA) is 2024-11-13 Est..
Does Kintara Therapeutics Inc(STU:3DMA) pay dividends? If so, how much?
Kintara Therapeutics Inc(STU:3DMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers